The appointment of PHRI Senior Scientist Guillaume (Gui) Paré as the new Deputy Director of the Thrombosis and Atherosclerosis Research Institute (TaARI) deepens and formalizes the years-long collaboration between PHRI and TaARI.
We are focused on bridging basic science (such as conducted at TaARI) and PHRI’S clinical and population research to develop a world-class translational research program.
He has also long been a member of TaARI’s Experimental Thrombosis and Atherosclerosis (ETA) program that, using a bench-to-bedside approach, explores the complex interplay among genetic, environmental and stochastic factors that impair vascular health and trigger thrombosis.
The ETA program, and TaARI as an institute, is led by Jeffrey Weitz, current president of the International Society on Thrombosis and Haemostasis (ISTH). TaARI’s ETA program also includes PHRI Senior Scientist John Eikelboom, whose research focus includes the efficacy and safety of antithrombotic therapies.
John, Gui and PHRI Investigator Noel Chan are working on PHRI’s ACT COAG (assessing coagulation biomarkers to accelerate the discovery of effective therapies for COVID-19) study in collaboration with TaARI’s Jeff Weitz and Paul Kim – one of many cooperative research projects the two institutes have undertaken together over the years, with much more planned for the years to come.
Collaboration is made easier, too (especially once we’re post-pandemic) by the fact that PHRI and TaARI both reside in the David Braley Cardio Vascular and Stroke Research Institute building in Hamilton, Canada.